Lees Pharmaceutical Hldgs 

$0.190300
2
+$0.00+1.12% Monday 20:00

Statistics

Day High
0.2
Day Low
0.2
52W High
0.2
52W Low
0.1882
Volume
6,000
Avg. Volume
0
Mkt Cap
112.06M
P/E Ratio
18.82
Dividend Yield
3.06%
Dividend
0.01

Upcoming

Dividends

3.06%Dividend Yield
Jun 26
$0.00
Oct 25
$0.00
Jun 25
$0.00
Oct 24
$0.00
Jun 24
$0.00
10Y Growth
-8.35%
5Y Growth
-5.99%
3Y Growth
35.84%
1Y Growth
-4.21%

Earnings

2SepExpected
Q4 2017
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
0.08
0.09
0.1
0.11
Expected EPS
N/A
Actual EPS
N/A

Financials

6.65%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
360.03MRevenue
23.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LPCUF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap2.07B
Zai Lab Limited operates in the biopharmaceutical industry in China, focusing on bringing transformative medicines for cancer, autoimmune and infectious diseases, directly competing with Lees in these therapeutic areas.
HUTCHMED (China) Limited
HCM
Mkt Cap1.74B
Hutchison China MediTech Limited, known as Chi-Med, is involved in the innovation, manufacture, and sale of pharmaceuticals and health-related consumer products, competing in the same regional market and sectors as Lees.
Sinovac Biotech
SVA
Mkt Cap642.44M
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases, competing with Lees in the biopharmaceutical sector.
China Pharma
CPHI
Mkt Cap31.25M
China Pharma Holdings, Inc. develops, manufactures, and markets specialty pharmaceutical products in China, directly competing with Lees Pharmaceutical in the Chinese pharmaceutical market.
GSK
GSK
Mkt Cap101.54B
GlaxoSmithKline plc, a leading global pharmaceutical company, competes across various therapeutic areas including those targeted by Lees, such as immunology and oncology.
Merck
MRK
Mkt Cap281.24B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across multiple segments including cancer, directly competing with Lees Pharmaceutical in the oncology market.
Pfizer
PFE
Mkt Cap143.68B
Pfizer Inc. is a global pharmaceutical corporation which develops and manufactures drugs and vaccines for a wide range of medical disciplines, including those areas where Lees operates, making it a competitor.

About

Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the distribution and commercialization of pharmaceutical products obtained through licensing agreements with other companies. This extensive portfolio encompasses treatments such as Carnitene for carnitine deficiency; Aloxi and Sancuso for managing chemotherapy-induced nausea and vomiting; Bredinin, an immunosuppressant used in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil, which alleviates oral mucositis pain; Ferplex for iron deficiency anemia; and Gaslon N for gastric ulcers and gastritis. Additional offerings include Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution for primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan, indicated for Stage III and IV Hodgkin's disease; Omacor, containing Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik for Amyotrophic lateral sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; the probiotics Dicoflor and VSL#3; and Zingo, a topical local analgesic. Lee's Pharmaceutical was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Show more...
CEO
Ms. Siu Fong Lee
Employees
1022
Country
Cayman Islands
ISIN
KYG5438W1116

Listings

0 Comments

Share your thoughts

FAQ

What is Lees Pharmaceutical Hldgs stock price today?
The current price of LPCUF is $0.19 USD — it has increased by +1.12% in the past 24 hours. Watch Lees Pharmaceutical Hldgs stock price performance more closely on the chart.
What is Lees Pharmaceutical Hldgs stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lees Pharmaceutical Hldgs stocks are traded under the ticker LPCUF.
What is Lees Pharmaceutical Hldgs market cap?
Today Lees Pharmaceutical Hldgs has the market capitalization of 112.06M
When is the next Lees Pharmaceutical Hldgs earnings date?
Lees Pharmaceutical Hldgs is going to release the next earnings report on September 02, 2026.
What is Lees Pharmaceutical Hldgs revenue for the last year?
Lees Pharmaceutical Hldgs revenue for the last year amounts to 360.03M USD.
What is Lees Pharmaceutical Hldgs net income for the last year?
LPCUF net income for the last year is 23.93M USD.
Does Lees Pharmaceutical Hldgs pay dividends?
Yes, LPCUF dividends are paid semi-annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 3.06%.
How many employees does Lees Pharmaceutical Hldgs have?
As of June 23, 2026, the company has 1,022 employees.
In which sector is Lees Pharmaceutical Hldgs located?
Lees Pharmaceutical Hldgs operates in the Health & Wellness sector.
When did Lees Pharmaceutical Hldgs complete a stock split?
Lees Pharmaceutical Hldgs has not had any recent stock splits.
Where is Lees Pharmaceutical Hldgs headquartered?
Lees Pharmaceutical Hldgs is headquartered in Sha Tin, Cayman Islands.